Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a
Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a technetium-labeled agent. DuPont Merck, of North Billerica, MA, plans to begin shipping Neurolitein January. The product is indicated for brain perfusion studiesin stroke patients (SCAN 9/14/94).
Study Raises Doubt About AI Sensitivity for Smaller and Multiple Findings on Chest X-Rays
September 29th 2023In a multicenter study examining four commercially available artificial intelligence (AI) software products for chest X-rays in over 2,000 patients, researchers found sensitivity rates ranging between 33 to 61 percent for vague airspace disease and 9 to 94 percent for small pneumothorax and pleural effusion.
Seven Takeaways from New Analysis of Malpractice Cases Involving Interventional Radiologists
September 27th 2023Thirty-five percent of the interventional radiology malpractice cases involved vascular procedures and 26 percent of overall malpractice cases that went to trial resulted in plaintiff judgments with the average award being over $2 million.
2 Clarke Drive
Cranbury, NJ 08512